Scholarlink

Objectives <p>To describe healthcare resource utilization (HCRU), direct costs, and survival of DLBCL patients in Sweden.</p> Methods <p>This retrospective cohort study followed adult patients with DLBCL from 2015 to 2023 using Swedish national registers. Time in specialty care was calculated as days per-person-year (PPY). Nordic diagnosis-related-group weights were used to estimate costs.</p> Results <p>7,503 patients were diagnosed with DLBCL. Median age was 73.0&#xa0;years; 56.9% male and 55.0% had ≥ 1 comorbidity. On average, patients spent 17.6&#xa0;days (4.8% annually) PPY in care, with average costs of €15,417 PPY. HCRU was highest in the first and second year with 41.7&#xa0;days (11.4%) and 12.6&#xa0;days (3.5%) in care, respectively. Average time in care declined from 13.7&#xa0;days (3.8%) in 2015 to 11.9&#xa0;days (3.3%) in 2019, then stabilized. Overall survival was 76.5% (95%CI: 75.5–77.4) and 68.9% (95%CI: 67.9–70.0) at 1 and 2&#xa0;years from diagnosis.</p> Conclusions <p>DLBCL patients spent considerable time in specialist care, especially in the first two years post-diagnosis. Care use and costs remained stable over the period. This study provides the first population-level estimates of HCRU and direct costs for DLBCL in Sweden, offering valuable context for current management and future integration of evolving treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world patterns of healthcare use, costs, and survival in diffuse large B-cell lymphoma: a nationwide Swedish register study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月13日

查看全文
  • Eva Herweijer,
  • Kaisa Miikkulainen,
  • Oskar Eklund,
  • Brett Doble,
  • Christoffer Holmberg,
  • Viktor Hedlöf Kanje,
  • Robyn Thorén,
  • Christina Victoria Jones,
  • Magnus Björkholm

摘要

Objectives

To describe healthcare resource utilization (HCRU), direct costs, and survival of DLBCL patients in Sweden.

Methods

This retrospective cohort study followed adult patients with DLBCL from 2015 to 2023 using Swedish national registers. Time in specialty care was calculated as days per-person-year (PPY). Nordic diagnosis-related-group weights were used to estimate costs.

Results

7,503 patients were diagnosed with DLBCL. Median age was 73.0 years; 56.9% male and 55.0% had ≥ 1 comorbidity. On average, patients spent 17.6 days (4.8% annually) PPY in care, with average costs of €15,417 PPY. HCRU was highest in the first and second year with 41.7 days (11.4%) and 12.6 days (3.5%) in care, respectively. Average time in care declined from 13.7 days (3.8%) in 2015 to 11.9 days (3.3%) in 2019, then stabilized. Overall survival was 76.5% (95%CI: 75.5–77.4) and 68.9% (95%CI: 67.9–70.0) at 1 and 2 years from diagnosis.

Conclusions

DLBCL patients spent considerable time in specialist care, especially in the first two years post-diagnosis. Care use and costs remained stable over the period. This study provides the first population-level estimates of HCRU and direct costs for DLBCL in Sweden, offering valuable context for current management and future integration of evolving treatment strategies.